Komori
Share Issuance and Disposal4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding Reduction of Capital and Appropriation of Other Capital Surplus

Capital will be reduced by ¥567.576 million to ¥10 million, and ¥3,460.412 million in other capital surplus will be transferred to retained earnings brought forward to offset the deficit. There will be no change in the number of shares or net assets, and the transaction will not involve fundraising or the issuance of shares.

Worth reading
27Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
567576
¥ thousand
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Reduction of capital (capital reduction without compensation) and appropriation of other capital surplus

発行済株式総数

No change

0% (no change in the total number of issued shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Procedures under the Corporate Code of Conduct
The matter will be submitted to the annual general meeting of shareholders scheduled for 24 April 2026, and the procedure is conditional upon approval.
Impact on Business Performance
There will be no impact on the Company’s results of operations.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReduction of capital (capital reduction without compensation) and appropriation of other capital surplus
Dilution Rate0% (no change in the total number of issued shares)
Total number of issued sharesNo change
Procedures under the Corporate Code of ConductThe matter will be submitted to the annual general meeting of shareholders scheduled for 24 April 2026, and the procedure is conditional upon approval.
Impact on Business PerformanceThere will be no impact on the Company’s results of operations.
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To offset the deficit and ensure flexibility and agility in future capital policies, thereby strengthening the Company’s financial position.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Reduction of Capital and Appropriation of Other Capital Surplus | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori